How We Work

Grant

Back

Print

Takeda Pharmaceutical Company, Ltd


May 2016
to increase total global capacity to meet potential demand for Inactivated Poliovirus Vaccine (IPV) in 2019/2020, and ensure adequate vaccine supply at an affordable cost.
$40,500,000
59
Polio
Global Development
osaka-shi
http://www.takeda.com

Visit Our Blog